Legend Biotech Corporation (LEGN)
Company Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.
It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel.
The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Country | United States |
Founded | 2014 |
IPO Date | Jun 5, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 1,826 |
CEO | Dr. Ying Huang Ph.D. |
Contact Details
Address: 2101 Cottontail Lane Somerset, New Jersey 08873 United States | |
Phone | 732-317-5050 |
Website | legendbiotech.com |
Stock Details
Ticker Symbol | LEGN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $23.00 |
CIK Code | 0001801198 |
CUSIP Number | 52490G102 |
ISIN Number | US52490G1022 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Ying Huang Ph.D. | Chief Executive Officer and Director |
Doug Wallace | Vice President of Global Operations |
Dr. Guowei Fang Ph.D. | Chief Scientific Officer and Head of Business Development |
Joanne Choi | Senior Manager of Investor Relations |
James Pepin J.D. | General Counsel |
Deborah Wong | Executive Director of Strategic Marketing and Corporate Communications |
Elaine Qian | Vice President and Global Head of Human Resources |
Dr. Yuhong Qiu Ph.D. | Senior Vice President of Global Regulatory Affairs |
Steven J. Gavel | Senior Vice President of Commercial Development, US and Europe |
Alan Kick | Senior Vice President of Global Quality |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2024 | 144 | Filing |
Mar 26, 2024 | 144 | Filing |
Mar 25, 2024 | 144 | Filing |
Mar 25, 2024 | 144 | Filing |
Mar 19, 2024 | 144 | Filing |
Mar 19, 2024 | F-3ASR | Filing |
Mar 19, 2024 | 20-F | Annual and transition report of foreign private issuers |
Mar 15, 2024 | 6-K | Report of foreign issuer |
Mar 13, 2024 | 6-K | Report of foreign issuer |
Mar 11, 2024 | 6-K | Report of foreign issuer |